CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population

[1]  M. Kool,et al.  Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions. , 2022, European journal of medical genetics.

[2]  M. Frosch,et al.  Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions , 2022, Acta Neuropathologica.

[3]  Y. Wang,et al.  CNS tumor with BCOR internal tandem duplication: Clinicopathologic, molecular characteristics and prognosis factors. , 2022, Pathology, research and practice.

[4]  O. Delattre,et al.  Intra‐ and extra‐cranial BCOR‐ITD tumours are separate entities within the BCOR ‐rearranged family , 2022, The journal of pathology. Clinical research.

[5]  H. Brisse,et al.  Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication , 2021, American Journal of Neuroradiology.

[6]  P. Varlet,et al.  BCOR immunohistochemistry, but not SATB2 immunohistochemistry, is a sensitive and specific diagnostic biomarker for central nervous system tumours with BCOR internal tandem duplication , 2021, Histopathology.

[7]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[8]  A. Manabe,et al.  High‐grade neuroepithelial tumor with BCL6 corepressor‐alteration presenting pathological and radiological calcification: A case report , 2021, Pathology international.

[9]  P. Varlet,et al.  The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of “CNS tumors with BCOR internal tandem duplication” , 2020, Acta Neuropathologica Communications.

[10]  P. Varlet,et al.  The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of “CNS tumors with BCOR internal tandem duplication” , 2020, Acta neuropathologica communications.

[11]  V. Santosh,et al.  Central nervous system high grade neuroepithelial tumor with BCOR immunopositivity: Is there a molecular heterogeneity? , 2020, Brain Tumor Pathology.

[12]  W. Grajkowska,et al.  Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes , 2020, Acta Neuropathologica Communications.

[13]  M. Kool,et al.  A single supratentorial high‐grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival , 2020, Pediatric blood & cancer.

[14]  M. Aboian,et al.  High‐grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication—a comprehensive clinical, radiographic, pathologic, and genomic analysis , 2019, Brain pathology.

[15]  C. Sommer,et al.  IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients , 2019, International journal of molecular sciences.

[16]  A. Perry,et al.  A Cerebellar High-Grade Neuroepithelial Tumour with BCOR Alteration in a five-year-old Child , 2019, Sultan Qaboos University medical journal.

[17]  K. Makino,et al.  Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors , 2018, Acta neuropathologica communications.

[18]  Y. Arakawa,et al.  CNS high‐grade neuroepithelial tumor with BCOR internal tandem duplication: a comparison with its counterparts in the kidney and soft tissue , 2018, Brain pathology.

[19]  T. Jacques,et al.  Early Wound Site Seeding in a Patient with Central Nervous System High-Grade Neuroepithelial Tumor with BCOR Alteration. , 2018, World neurosurgery.

[20]  C. Sommer,et al.  Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy , 2017, Oncotarget.

[21]  M. Kool,et al.  HGNET-BCOR Tumors of the Cerebellum: Clinicopathologic and Molecular Characterization of 3 Cases , 2017, The American journal of surgical pathology.

[22]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.